Pages that link to "Q40240678"
Jump to navigation
Jump to search
The following pages link to Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib (Q40240678):
Displaying 37 items.
- Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas (Q33750719) (← links)
- Recent advances in the regulation of cholangiocarcinoma growth (Q33994814) (← links)
- HER-2/neu diagnostics in breast cancer (Q35906255) (← links)
- Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach (Q36177918) (← links)
- JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression? (Q36178175) (← links)
- Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice (Q36544718) (← links)
- Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment (Q36950063) (← links)
- Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives (Q36962011) (← links)
- Emerging drugs for biliary cancer (Q36989921) (← links)
- Emerging drugs for the treatment of metastatic renal cancer. (Q36989925) (← links)
- Diagnosis and management of cholangiocarcinoma. (Q37140020) (← links)
- Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma (Q37177871) (← links)
- Evolving therapies in the treatment of hepatocellular carcinoma (Q37290714) (← links)
- Imaging of EGFR and EGFR tyrosine kinase overexpression in tumors by nuclear medicine modalities. (Q37320501) (← links)
- Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma (Q37351498) (← links)
- Targeted therapy in biliary tract cancer: 2009 update. (Q37650623) (← links)
- Dual inhibition: a novel promising pharmacological approach for different disease conditions (Q37852762) (← links)
- Targeted therapy for biliary tract cancers (Q37982650) (← links)
- Molecular aspects of cholangiocarcinoma (Q38178190) (← links)
- Clinical aspects and perspectives of erlotinib in the treatment of patients with biliary tract cancer. (Q38701620) (← links)
- Multi-OMIC profiling of survival and metabolic signaling networks in cells subjected to photodynamic therapy. (Q38734193) (← links)
- Bile acid accelerates erbB2-induced pro-tumorigenic activities in biliary tract cancer (Q38993903) (← links)
- The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice (Q39397936) (← links)
- Role of ErbB/HER family of receptor tyrosine kinases in cholangiocyte biology. (Q39410914) (← links)
- The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines (Q39422598) (← links)
- Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer (Q39642981) (← links)
- Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy (Q39683530) (← links)
- Effect of histone deacetylase inhibitor on proliferation of biliary tract cancer cell lines (Q39987553) (← links)
- Targeted medical therapy of biliary tract cancer: recent advances and future perspectives (Q42635172) (← links)
- Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives (Q43097453) (← links)
- Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer (Q43141124) (← links)
- The anti-proliferative side effects of AEE788, a tyrosine kinase inhibitor blocking both EGF- and VEGF-receptor, are liver-size-dependent after partial hepatectomy in rats (Q47445868) (← links)
- Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan (Q50738801) (← links)
- The Influence of Bisphenol A (BPA) on Neuregulin 1-Like Immunoreactive Nerve Fibers in the Wall of Porcine Uterus (Q57066635) (← links)
- Cholangiocarcinoma: expanding the spectrum of risk factors (Q64044086) (← links)
- Establishment of a novel orthotopic xenograft model of human gallbladder carcinoma (Q80094301) (← links)
- Cholangiocarcinoma treatment (Q84962121) (← links)